Ifebemtinib (tosylate)

Ifebemtinib (tosylate) (BI-853520 (tosylate) ; IN-10018 (tosylate) ) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma[1][2][3][4].

Product Specifications

CAS Number

[2761021-80-9]

Product Name Alternative

BI-853520 (tosylate) ; IN-10018 (tosylate)

UNSPSC

12352005

Target

FAK

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O=C(C1=C(F)C=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC4=C3C(N(C4)C)=O)=N2)C(OC)=C1)NC5CCN(CC5)C.O=S(O)(C6=CC=C(C)C=C6)=O

Molecular Formula

C35H36F4N6O7S

Molecular Weight

760.75

References & Citations

[1]Laszlo, V., et al., (2019) . The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal of molecular medicine (Berlin, Germany), 97 (2), 231–242. |[2]Verheijen, R. B., et al., (2019) . Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Targeted oncology, 14 (1), 67–74.|[3]Tiede, S., et al., (2018) . The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7 (9), 73. |[4]Marabelle, A., et al., (2020) . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology, 21 (10), 1353–1365.